美股价在宣布一种新的脑穿透药物治疗帕金森病后大幅上升. Galmed shares surged after announcing a new brain-penetrating formulation for treating Parkinson's.

美药业股价在宣布其新型大脑毒品阿兰科尔的推出后大幅上升. Galmed Pharmaceuticals shares surged after announcing a new brain-penetrating formulation of its drug Aramchol. 这项创新使用脂质纳米粒子穿越血脑屏障, 潜在治疗帕金森病和痴呆症. Developed with Barcode Nanotech, this innovation uses lipid nanoparticles to cross the blood-brain barrier, potentially treating Parkinson's disease and dementia. 临床前研究表明该药物可降低α-同核素聚合,公司计划在2026年开始进行临床试验. Preclinical studies showed the drug reduces alpha-synuclein aggregation, and the company plans to begin clinical trials in 2026.